Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793284 | 0.83 | GAA (0.58) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL25086292 | 0.82 | PRKCQ (0.50) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL2789608 | 0.81 | LMNA (0.59) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL2789965 | 0.81 | MAPT (0.55) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL21464112 | 0.79 | GAA (0.57) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL4066108 | 0.79 | LMNA (0.58) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL1473102 | 0.79 | LMNA (0.58) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL26675754 | 0.78 | GAA (0.56) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL30716719 | 0.78 | GAA (0.56) | HDAC8MAPTMEN1KMT2ALMNA | |
| SCHEMBL26675757 | 0.78 | GAA (0.56) | HDAC8MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| EP-2074123-B1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| EP-2074123-A1 | NOVEL ANXIOLYTIC COMPOUNDS | Bionomics Limited (AU) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | HDAC8 971/4885MAPT 1400/4885MEN1 2882/4885 |
| US-10233181-B2 | Anxiolytic compounds | GABBR1, GABRA6, SLC18A2 | HDAC8 1341/4885MAPT 1130/4885MEN1 1529/4885 |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | HDAC8 1062/4885MAPT 1438/4885MEN1 2584/4885 |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | HDAC8 1062/4885MAPT 1438/4885MEN1 2584/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | HDAC8 1066/4885MAPT 929/4885MEN1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.